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Cardiac	 myosin	 binding	 protein-C	 (cMyBP-C)	 is	 a	 fundamental	 component	 of	 the	 cardiac	 sarcomere	
involved	in	regulating	systolic	and	diastolic	activity,	processes	which	must	be	tightly	maintained	to	preserve	
cardiac	 function.	 Importantly,	 as	 a	 non-enzymatic	 protein,	 cMyBP-C	 relies	 solely	 on	 post-translational	







(MyBP-C)1.	 Named	 C-protein	 by	 its	 original	 discovery	 as	 a	 contaminant	 of	 a	 cardiac	myosin	 preparation	
(with	each	contaminant	given	a	letter	based	on	their	size	compared	to	myosin	heavy	chain),	MyBP-C	can	be	
found	localised	as	distinctly	spaced	stripes	of	the	C-zone	of	the	A	band,	where	due	to	its	abundance	it	was	
initially	 considered	 a	 purely	 structural	 component	 of	 the	 sarcomere1,2.	 Although	 it	 does	 play	 a	 role	 in	
stability	via	C-terminal	interactions	with	the	light	meromyosin	(LMM)	component	of	the	myosin	backbone3	
and	 giant	 sarcomeric	 protein	 Titin4,	 cMyBP-C	 is	 now	 best	 known	 as	 an	 essential	 regulator	 of	 cardiac	
contractility.	 Additionally,	 it	 is	 a	 protein	 that	 is	 significantly	 influenced	 by	 a	 variety	 of	 post-translational	
modifications	(PTMs),	some	of	which	are	 important	clinically.	This	graphical	review	will	briefly	outline	the	
functional	 role	 of	 cMyBP-C	 in	 the	 sarcomere	 before	 discussing	 the	 past	 and	 recent	 advancements	 in	
understanding	its	regulation	by	PTMs.	
CMyBP-C	in	the	Control	of	Cardiac	Contractility	
Following	 the	 advancement	 in	 biochemical	 sequencing,	 the	 C-protein	 identified	 in	 skeletal	 muscle	 was	
found	 to	 exist	 as	 three	 paralogues	 on	 three	 different	 genes,	 two	 in	 the	 skeletal	 muscle	 (fast	 skeletal,	
fsMyBP-C	and	slow	skeletal,	 ssMyBP-C)	and	one	exclusively	expressed	 in	 the	atria	and	ventricles	of	heart	
(cardiac,	cMyBP-C)5,6,	which	contains	several	specific	cardiac	modifications.	Additionally,	a	smaller	protein,	











Although	 important	 research	 has	 been	 conducted	 to	 understand	 the	 function	 of	 the	 skeletal	 isoforms	
(reviewed	 by	 McNamara	 and	 Sadayappan9),	 most	 studies	 have	 focussed	 on	 the	 regulation	 of	 cardiac	
isoform.	This	is	largely	due	to	a	significant	advance	in	the	1990s	when	two	mutations	in	the	MYBPC3	gene	
that	 encodes	 the	 protein	 were	 shown	 to	 cause	 hypertrophic	 cardiomyopathy	 (HCM)10,11,	 a	 heritable	
condition	 resulting	 in	 left	 ventricular	 hypertrophy	 and	 diastolic	 dysfunction,	 that	 affects	 1:200	 in	 the	




myosin	 functional	 relationship.	 It	 was	 subsequently	 revealed	 that	 the	 cMyBP-C	 N-terminal	 domains	 can	
extend	from	the	myosin	backbone	and	interact	with	the	S2	region	of	myosin	heavy	chain,	found	C-terminal	
to	 the	 S1	motor	 head13.	 Functionally,	 knock-out	 models	 and	 ablation	 studies	 show	 that	 cMyBP-C	 has	 a	
minimal	role	in	maintaining	sarcomere	stability	but	a	significant	role	in	the	modulation	of	contraction,	with	
its	 absence	 resulting	 in	 accelerated	 cross-bridge	 formation,	 impaired	 diastolic	 function	 and	 reduced	
myofilament	calcium	sensitivity14–16.	This	hypercontractility	could	be	reversed	by	 introducing	the	C1-M-C2	







vitro	motility	 assays	 initially	 revealed	 cMyBP-C	 inhibits	 actin	motion24,	 but	 addition	of	 regulatory	protein	
tropomyosin	saw	cMyBP-C	increase	actin	motility	at	low	calcium25.	Current	work	suggests	cMyBP-C	has	dual	
inhibitory	and	activating	effects	through	its	interaction	with	actin	and	tropomyosin,	with	the	C0-C1	domains	
competing	 for	actin	binding	with	 tropomyosin,	 thus	 shifting	 tropomyosin	 to	 its	high	 calcium	state	at	 low	
calcium,	 leading	 to	 increased	 actin	 activation,	 enhanced	 calcium	 sensitivity	 and	 prolonged	 relaxation26,27	
(Figure	2).		
	
Figure	 2:	 Cardiac	Myosin	 Binding	 Protein-C	 in	 the	 Sarcomere.	Cardiac	myosin	 binding	 protein-C	 (cMyBP-C)	 is	 found	 at	 regular	
intervals	 (43nm	apart)	 in	 the	C-zone	of	 the	A	band	of	 the	sarcomere	where	 it	 is	anchored	 through	 interactions	of	 its	C-terminal	
domains	with	 the	 light	meromyosin	 component	 of	 the	myosin	 thick	 filament,	 as	well	 as	 interactions	with	 the	 giant	 sarcomeric	






the	calcium	sensing	 troponin	complex	 formed	of	 troponin-T	 (TnT),	 troponin-C	 (TnC)	and	Troponin-I	 (TnI)	 that	when	activated	by	
calcium	during	systole,	shift	the	tropomyosin	molecule	from	its	low	to	high	calcium	state	exposing	binding	sites	for	myosin.	CMyBP-




the	 idea	that	cMyBP-C	acts	as	an	 inhibitor	of	acto-myosin	cross-bridge	 formation	and	an	overall	negative	
regulator	 of	 cardiac	 contractility.	 However,	 influence	 from	 a	 variety	 of	 PTMs	 greatly	 complicates	 this	
picture.	 During	 times	 of	 increased	 cardiac	 demand,	 activation	 of	 β1	 adrenoceptors	 leads	 to	 a	 signalling	
cascade	 resulting	 in	 protein	 kinase	 A	 (PKA)	 phosphorylation	 of	 downstream	 substrates,	 including	
sarcomeric	 proteins,	 and	 modulation	 of	 their	 activity	 in	 response28.	 CMyBP-C	 phosphorylation	 was	 first	
identified	 in	 isoproterenol	 treated	 frog	 cardiac	 tissue29,	 and	 extensive	 research	 since	 has	 shown	 the	
profound	effect	cMyBP-C	phosphorylation	has	on	overall	myocardial	contractility.	 In	fact,	nearly	all	of	the	
interactions	described	above	are	influenced	by	phosphorylation,	leading	to	reduced	binding	of	cMyBP-C	to	
myosin	S230	and	actin31,	which	 results	 in	 increased	cross-bridge	 formation,	 calcium	sensitivity	and	overall	
enhanced	inotropic	and	lusitropic	response32,33.		
An	 initial	 study	 identified	 three	 serines	 in	 the	 cMyBP-C	M-domain	 to	be	phosphorylated	 (Ser273,	 Ser282	




phenotype	 of	 the	 cMyBP-C-null	 mouse,	 whereas	 wildtype	 and	 phospho-mimetic	 expression	 restored	
cardiac	 function34,35.	 Importantly,	 phospho-mimetic	 mice	 were	 protected	 against	 cardiac	
ischaemia/reperfusion	injury35	and	it	has	been	since	shown	that	phosphorylation	of	cMyBP-C	is	significantly	
reduced	in	both	experimental	and	human	heart	failure36,37.	Interestingly,	a	recent	study	has	shown	cMyBP-
C	phosphorylation	 in	mice	decreases	with	age,	 and	phospho-mimetic	mice	 show	enhanced	 survival,	with	
preserved	cardiac	function	and	ventricular	wall	thickness38.	It	has	also	been	recently	reported	that	cMyBP-C	
plays	more	of	a	role	in	regulating	calcium	homeostasis	than	initially	thought,	with	reduced	phosphorylation	
correlating	 with	 prolonged	 calcium	 transients	 and	 increased	 diastolic	 calcium	 levels,	 potentially	 through	
changes	in	the	sodium-calcium	exchanger	function39.		
Phosphorylation	of	cMyBP-C	 is	essential	 to	maintain	cardiac	function,	however	the	processes	that	govern	
this	modification	are	complex.	Additional	work	has	 further	defined	 the	 roles	of	 these	 sites,	 showing	 that	









fibrosis,	 and	 reduced	 survival	 into	 adulthood.	 However,	when	 S282	 is	 constitutively	 phosphorylated	 (aspartate	 substitution,	 D),	
even	when	the	other	two	sites	are	unphosphorylatable,	transgenic	mice	have	normal	cardiac	function	compared	to	wildtype,	and	
improved	levels	of	hypertrophy,	fibrosis	and	survival	compared	to	S282A,	implicating	it	as	the	critical	phosphorylation	site	in	the	M	





phosphorylation	 by	 PKC	 isoforms	 PKCε	 and	 PKCα	 lead	 to	 decreased	 myofibrillar	 ATPase	 activity	 and	
reduced	 calcium	 sensitivity41,44.	 PKD,	 activated	 through	 PKC	 directed	 phosphorylation,	 increases	 cross-
bridge	formation	through	phosphorylation	of	Ser302,	analogous	to	PKA	directed	phosphorylation	of	the	M-
domain45.	 Interestingly,	 although	 known	 to	 be	 the	 critical	 phosphorylation	 site	 of	 cMyBP-C	 by	 PKA,	
mutation	 of	 Ser282	 does	 not	 alter	 PKD	 dependent	 regulation45.	 M-domain	 phosphorylation	 produces	
distinct	 functional	profiles	 in	 cMyBP-C,	 in	 terms	of	 regulating	 the	 interaction	with	actin	 and	myosin,	 and	
overall	effect	on	cardiac	contractility46.		
Aside	 from	 PKA,	 PKC	 and	 PKD	 regulation,	 the	 M-domain’s	 Ser302	 and	 Ser282	 are	 phosphorylated	 by	
Ca2+/calmodulin-dependent	 protein	 kinase	 II	 (CAMKII),	 and	 as	 a	 calcium-sensitive	 kinase,	 the	 extent	 to	
which	phosphorylation	occurs	may	be	regulated	by	calcium	concentration41.	Functionally,	phosphorylation	
of	 S302	 by	 CAMKII	 may	 play	 a	 role	 in	 positive	 force-frequency	 relationship	 of	 cardiac	 tissue47.	
Phosphorylation	 by	 ribosomal	 S6	 kinase	 (RSK)	 has	 been	 reported,	 whereby	 activation	 in	 response	 to	
mitogen-activated	protein	kinase	pathway	results	in	RSK	phosphorylation	at	a	single	site	(S282),	leading	to	
increased	cross-bridge	kinetics	and	reduced	myofilament	calcium	sensitivity,	and	may	be	required	for	PKA	
mediated	 phosphorylation	 of	 other	 sites48.	 More	 recent	 study	 suggests	 the	 M-domain	 phosphorylation	
complexity	allows	cMyBP-C	to	direct	particular	affects	over	the	thick	and	thin	filaments	in	control	of	cross-
bridge	 cycling,	 and	 that	 phosphorylation	 of	 a	 site	 by	 one	 kinase	 can	 positively	 or	 negatively	 impact	 the	
phosphorylation	 by	 additional	 kinases	 on	 other	 sites46.	 Understanding	 of	 cMyBP-C	 phosphorylation	 is	
expanding	 over	 time,	 with	 in-vivo	 mass	 spectrometry	 evidence	 suggesting	 there	 could	 be	 up	 to	 24	
phosphorylation	 sites	 present	 on	 cMyBP-C49,50.	 Of	 note,	 S307	 has	 been	 implicated	 as	 a	 potential	 PKA	
phosphorylation	site,	although	there	was	limited	evidence	of	this	in-vivo51.	Additionally,	S133,	a	site	in	the	







targets	 both	 S273	 and	 S302	 while	 protein	 kinase	 D	 only	 targets	 S302.	 Other	 phosphorylating	 kinases	 identified	 include	
Ca2+/calmodulin-dependent	protein	kinase	II	(CAMKII),	which	targets	S282	and	S302,	ribosomal	S6	kinase	(RSK),	which	only	targets	





such	 as	 carbonylation,	 S-nitrosylation	 and	 S-glutathionylation	 are	 often	 enhanced	 in	 times	 of	 oxidative	




protein	 carbonylation	 is	 increased	 in	 the	 failing	 human	 heart53	 and	 has	 been	 studied	 in	 the	 functional	
regulation	of	the	ryanodine	receptor	2	(RYR2)	and	Na+/Ca	ATPase	(SERCA)54.	A	proteomics	screen	revealed	
cMyBP-C	carbonylation	in	response	to	Doxorubicin	treatment,	an	anti-cancer	agent	with	restricted	use	due	
to	 cardiotoxicity	 issues,	 and	 demonstrated	 cMyBP-C	 degradation	 through	 the	 proteasomal	 pathway	 and	
potential	carbonylation-mediated	dysregulation	of	actin	binding.	Although	the	functional	consequences	are	
not	 yet	 understood,	 this	 could	 implicate	 cMyBP-C	 and	 loss	 of	 binding	 to	 actin	 in	 the	 pathology	 of	






decreased	 calcium	 sensitivity,	 decreased	 maximal	 isometric	 force	 and	 prolonged	 relaxation	 following	 S-




modification	 that	 has	 shown	 the	 most	 promise	 in	 this	 respect	 is	 the	 S-glutathionylation	 of	 cMyBP-C,	
involving	 the	 reversible	 addition	 of	 a	 glutathione	 (GSH)	molecule	 to	 the	 thiol	 of	 a	 cysteine	 residue	 via	 a	
disulphide	bond.	This	modification	plays	a	number	of	 roles	 including	altering	protein-protein	 interactions	
and	 is	 implicated	 in	 cardiac	 pathophysiology	 with	 overall	 S-glutathionylation	 being	 increased	 following	
ischaemia/reperfusion62,63.	 An	 initial	 proteomic	 study	 using	 a	 biotinylated	 pulldown	 approach	 from	 rat	
hearts	 revealed	 cMyBP-C	 to	 be	 one	 of	 eleven	 S-glutathionylated	 proteins	 identified64.	 Interest	 in	 its	
functional	 significance	 developed	 after	 one	 group	 showed	 enhanced	 glutathionylation	 of	 cMyBP-C	 in	 a	
DOCA-salt	 model	 of	 hypertensive	 stress,	 and	 reversal	 of	 the	 oxidative	 stress	 led	 to	 improved	 diastolic	
function	 and	 increased	 cross	 bridge	 formation65,66.	 A	 follow	 up	 study	 identified	 three	 S-glutathionylated	
cysteines	in	the	lesser	studied	central	C3-C5	region	of	the	protein	(C479,	C627,	C655;	mouse	sequence)	and	
later	an	additional	cluster	of	cysteines	 in	 the	N-terminus	of	 the	protein	were	 identified.	 Importantly,	 this	
studied	 demonstrated	 enhanced	 glutathionylation	 of	 cMyBP-C	 in	 human	 samples	 from	 ischaemic	 and	
dilated	 cardiomyopathy	 and	 showed	 that	 S-glutathionylation,	 at	 C249	 in	 particular,	 negatively	 regulates	
cMyBP-C	PKA	and	CAMKII	mediated	phosphorylation,	leading	to	enhanced	myosin	S2	binding	and	reduced	







substrates.	 In	 terms	 of	 the	 myofilament,	 a	 	 seminal	 report	 identified	 sarcomere-associated	 acetylation	
enzymes	 and	 showed	 that	 enhanced	 acetylation	 increased	 myofilament	 contractility	 and	 calcium	
sensitivity67.	A	later	study	highlighted	that	inhibition	of	myosin	heavy	chain	deacetylation	led	to	enhanced	
ATPase	 activity	 and	 contractility	 dynamics68.	 Acetylation	 of	 cMyBP-C	 was	 first	 observed	 following	 high-




cMyBP-C	 R696	 citrullination,	 the	 irreversible,	 enzymatic	 conversion	 of	 an	 arginine	 residue	 to	 citrulline,	
often	leading	to	loss	of	protein	structure	and	protein-protein	interactions71.	Subsequent	investigation	into	
the	 functional	 consequences	 of	 citrullination	 on	 actin,	 troponin,	 tropomyosin	 and	myosin	 indicated	 that	




undergo	 phosphorylation	 at	 three	 serines	 (S273,	 S282	 and	 S302,	 mouse	 sequence)	 in	 the	 M-domain	 and	 one	 site	 in	 the	
proline/alanine	 rich	 linker,	 the	 overall	 effect	 of	which	 is	 a	 reduction	 in	 the	 inhibition	 of	myosin-actin	 cross-bridge	 formation	 by	
limiting	 cMyBP-C	 binding	 to	 both	 actin	 and	 myosin,	 allowing	 enhanced	 cross-bridge	 formation	 and	 positive	 inotropy.	
Phosphorylation	of	cMyBP-C	is	reduced	in	heart	failure	and	preservation	is	thought	to	be	beneficial.	Reactive	oxygen	species	(ROS)	
induced	S-glutathionylation	has	been	 implicated	at	many	sites	throughout	the	protein,	 including	three	sites	 in	the	central	 region	
(C478,	C627,	C665)	and	one	 in	 the	C1	domain	 (C249).	 S-glutathionylation	 increases	binding	 to	myosin	 S2	 to	 reduce	 cross-bridge	
formation	 and	 is	 increased	 in	 heart	 failure	 and	 found	 to	negatively	 regulate	 cMyBP-C	phosphorylation.	 S-nitrosylation,	 a	 similar	
post-translational	modification	involving	the	addition	of	nitric	oxide	(NO)	produced	by	nitric	oxide	synthase	(NOS)	to	the	thiol	of	a	
cysteine	residue,	has	been	reported	at	several	sites	 in	the	C10	domain	(highlighted	are	C1260	and	C1197/1198)	 involved	 in	 light	
meromyosin	and	 titin	binding,	 and	also	 in	 the	C5	domain	 (C715),	 although	 these	 sites	have	not	been	 confirmed	 in-vivo	and	 the	
specific	 functional	 consequences	 are	 not	 understood.	 Acetylation,	 involving	 the	 addition	 of	 an	 acetyl	 group	 via	 a	 histone	






have	 been	 limited	 in	 recent	 years.	 Although	 fundamental	 for	 our	 understanding	 of	 phosphorylation	 site	
non-equivalency,	 a	 recent	 study	 suggests	 that	 serine	 to	 aspartate	 mutants,	 designed	 to	 represent	
constitutive	phosphorylation,	do	not	fully	represent	the	effect	of	PKA	phosphorylation	in	vivo73.	However,	
transgenic	 animals	 such	 as	 these	 do	 allow	 a	 much	 more	 complete	 picture	 of	 the	 phosphorylation-




in-vivo	cMyBP-C	transgenic	models	studying	one	site	at	a	 time.	Recently,	 the	Harris	 lab	has	engineered	a	







as	 heart	 failure,	 is	 at	 the	 forefront.	 By	 far	 the	 most	 progress	 has	 been	 in	 the	 study	 of	 HCM	 and	 viral	
replacement	of	cMyBP-C	as	a	 therapeutic	strategy,	with	success	 in	ameliorating	 the	HCM	phenotype	and	
improving	cardiac	function	in	small	animal	models	showing	promising	results75,76.	In	terms	of	non-heritable	
disease,	 there	 is	 now	 clear	 evidence	 of	 cMyBP-C	 dysregulation,	 particularly	 that	 of	 phosphorylation,	 in	
hearts	 of	 patients	 with	 heart	 failure36,37,	 hypertension77	 and	 atrial	 fibrillation78,	 and	 it	 is	 clear	 that	
preservation	of	phosphorylation	in	particular	may	represent	a	therapeutic	strategy.	Currently,	work	in	small	
animal	models	shows	good	translational	potential,	for	example	the	evidence	that	S282	(mouse	sequence)	is	
the	most	 important	 site	 in	 animals	 and	 the	 site	 that	 displays	 the	most	 decreased	 in	 phosphorylation	 in	
humans40.	However,	progress	in	modulating	cMyBP-C	phosphorylation	therapeutically	may	be	hindered	by	




that	 producing	 single	 point	mutants	 to	 study	 a	modification	 in	 isolation	may	 inadvertently	 impact	 other	





of	 cardiac	 substrates.	 This	 limitation	 is	 especially	 relevant	 for	mutants	 of	 versatile	 amino	 acids,	 such	 as	
reactive	 cysteine	 thiols,	 that	 can	 undergo	 multiple	 modifications,	 such	 as	 S-glutathionylation,	 S-
nitrosylation	 and	 S-palmitoylation,	 as	 well	 as	 forming	 inter-	 and	 intra-	 protein	 disulphides.	 To	 fully	
understand	cMyBP-C	PTM	control,	it	is	imperative	that	sites	are	confirmed	in	vivo	to	gain	a	more	complete	
understanding	 of	 the	 functional	 significance	 of	 the	 modifications,	 and	 fortunately,	 the	 advancement	 in	
cMyBP-C	 and	 PTM	mass	 spectrometry	 and	 imaging	 in	 recent	 years	 will	 help	 to	 build	 a	 more	 complete	
profile.	
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